Purpura Treatment Market Research Report Information, by type (nonthrombocytopenic, thrombocytopenic) by drugs (corticosteroids, intravenous immunoglobulin (ivig), romiplostim (nplate), eltrombopag (promacta)) - Forecast to 2030

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Challenges

4.4 Opportunities

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining power of suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6 Global Purpura Treatment Market, By Type

6.1 Non-thrombocytopenic Purpura

6.2 Thrombocytopenic Purpura

6.3 Allergic Purpura

7 Global Purpura Treatment Market, By Cases

7.1 Acute

7.2 Chronic

8. Global Purpura Treatment Market, By Treatment

8.1 Corticosteroids

8.2 Intravenous Iimmunoglobulin

8.3 Other Drug Therapies

8.3.1 Romiplostim (Nplate)

8.3.2 Eltrombopag (Promacta)

9 Global Purpura Treatment Market, By Regions

9.1 Americas

9.1.1 North America

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 South America

9.2 Europe

9.2.1 Western Europe

9.2.1.1 Germany

9.2.1.2 France

9.2.1.3 UK

9.2.1.4 Italy

9.2.1.5 Spain

9.2.1.6 Rest of Western Europe

9.2.2 Eastern Europe

9.3 Asia Pacific

9.3.1 Japan

9.3.2 China

9.3.3 India

9.3.4 Australia

9.3.5 Republic of Korea

9.3.6 Rest of Asia-Pacific

9.4 Middle East & Africa

9.4.1 UAE

9.4.2 Saudi Arabia

9.4.3 Qatar

9.4.4 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Company Share Analysis

10.2 Key Development Landscape

10.2.1 Mergers & Acquisitions

10.2.2 Partnerships & Agreements

10.2.3 New Product Launch

10.2.4 Others

11 Company Profile

11.1 Amgen Inc

11.1.1 Company Overview

11.1.2 Product/Business Overview

11.1.3 Financial Overview

11.1.4 Key Developments

11.2 Bristol-Myers Squibb Company

11.2.1 Company Overview

11.2.2 Product overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.3 F. Hoffman-La Roche

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.4 GlaxoSmithKline Plc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.5 Grifols Biologicals Inc

11.5.1 Company Overview

11.5.2 Product overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Hovione

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Novartis AG

11.7.1 Company Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.8 Pfizer Inc.

11.8.1 Company Overview

11.8.2 Product Overview

11.8.3 Financial Overview

11.8.4 Key Developments

11.9 Sanofi

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial Overview

11.9.4 Key Developments

12 Bibliography